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Abstract
A number of genetic loci have been identified that appear to be
associated with systemic sclerosis (SSc; scleroderma). There is
mounting evidence suggesting that these genetic associations may
in fact be associated with distinct phenotypes in SSc based on
autoantibody pattern rather than with SSc as a single disease
entity. This may ultimately have implications for approaches to
therapy as well as responses to therapy. The most promising
candidate genes are those involved in pathways that lead to the
vascular damage and fibrosis that are the hallmarks of this disease.
There is uncertainty, however, regarding the nature of the key
pathological mechanisms that link these two disease processes.
Recent studies have focused on Fli1 (friend leukaemia integration
1), a transcription factor that is found in immune cells, fibroblasts,
and endothelial cells that regulates collagen gene function and
angiogenesis. Fli1 is dysregulated in SSc skin and dermal blood
vessels, and appears to play a pathological role in SSc skin fibrosis
and vessel degeneration. Whether this dysregulation is due to
genetic polymorphisms in the Fli1 pathway or to epigenetic
mechanisms is not clear.
Introduction
It is the generally accepted dogma that autoimmune disease
requires an external trigger to act upon a genetically
susceptible host. Identifying the underlying nature of this
susceptibility represents a considerable challenge that can
be attempted using a variety of approaches, including familial,
twin and genetic studies. This review begins by discussing
some of the available evidence for the existence of a genetic
component in systemic sclerosis (SSc; scleroderma). It then
focuses on studies conducted to determine the role played
by a particular gene product, Fli1 (friend leukaemia integra-
tion 1), whose dysregulation appears to contribute to the
complex pathogenesis of SSc in a number of ways.
Evidence for a genetic component to
systemic sclerosis
Familial studies
A positive family history is the strongest risk factor thus far
identified for SSc. A large US cohort-based study [1] found
that although the absolute risk in individual family members was
quite low (<1%), in a small but significant proportion of families
(1.6%) more than one first-degree relative was affected, giving
a familial relative risk of 13. A similar study in Australia [2]
reported a recurrence rate in families of approximately 1%,
which is in relative agreement with the US estimate of 1.6%.
In the current Scleroderma Family Registry of 693 index
cases, in 16 families more than one person is affected; there
are five sibling pairs and 11 parent-offspring pairs [3].
Unfortunately, the rarity of SSc precludes the generation of
meaningful genetic information from family-based linkage
studies, which have proved to be helpful in identifying genetic
associations in other more common autoimmune diseases
such as systemic lupus erythematosus and rheumatoid arthritis.
In general, studies of twins are considered the ‘gold
standard’ for determining whether a disease is due to shared
genetic predisposition or to shared environmental factors,
whereby a higher concordance rate for a disease is
expected in monozygotic than in dizygotic twins. In the only
published SSc twin study to date [4] the concordance rate
was low and no higher in monozygotic twins than in dizygotic
twins. However, the incidence of antinuclear antibody
positivity was higher in monozygotic twins than in dizygotic
twins (90% versus 40%), suggesting at least a greater
tendency toward disease in the former.
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Genome-wide studies
To date only one genome-wide association study in sclero-
derma has been reported. The Choctaw study [5] localized
chromosome regions associated with susceptibility to SSc in
a relatively isolated and homogeneous population of Choctaw
Indians with a high prevalence of SSc. The affected
individuals all had diffuse disease with pulmonary fibrosis,
with over 80% being positive for Scl70. The study identified a
total of 17 chromosome regions that were associated with
SSc, including some that overlapped with regions identified
in genome-wide studies of systemic lupus erythematosus and
rheumatoid arthritis (Table 1; for reviews see the reports by
Lee and Nath [6] and Etzel and coworkers [7]). One of the
regions identified in this way is the human leucocyte antigen
(HLA) region on 6p. The identity of other genes within these
regions is currently unknown. It will be interesting to see
respective data from a genome-wide scan in outbred non-
Choctaw populations that is currently being undertaken in a
study comparing approximately 5,000 SSc patients with
15,000 control individuals.
What are the candidate genes in systemic
sclerosis?
The choice of which candidate genes to study can be
daunting, considering the approximately 26,000 known
genes. There are several approaches to this dilemma. The
first is to choose genes in the regions that have been identi-
fied by the genome-wide scan [5]. The second is to study
genes that have been identified in other autoimmune
diseases and that appear to predispose to immune
dysregulation. The third is to choose genes that play a key
role in the aberrant pathways for a specific disease. As
outlined below, all three approaches have been used in the
study of scleroderma.
From a technical point of view, one of the methods used to
identify candidate genes associated with a disease involves
single nucleotide polymorphism (SNP) analysis. An SNP
defines a genetic locus in which two or more alleles have
gene frequencies greater than 1% in the population. SNP
maps can help to identify multiple genes associated with
complex diseases, which is difficult to achieve with
conventional gene-hunting methods, because a single altered
gene may make only a small contribution to the disease. The
SNPs of greatest interest are nonsynonymous SNPs, namely
those in which a single nucleotide change will yield a change
in the encoded protein.
A number of interesting polymorphisms or gene variations
have been associated with SSc (Table 2; for review, see the
report by Assassi and Tan [8]), some of which are discussed
in more detail below. However, one should bear in mind that
SSc is a heterogeneous disease with multiple subtypes and
that associations with particular polymorphisms may be
based on the ethnic background of the populations studied.
For example, although one report suggests an association of
endothelial nitric oxide synthase with SSc [9], other groups
found no such association [10,11]. In general, disease
associations with particular SNP polymorphisms are usually
not considered ‘true’ until they have been confirmed in an
independent cohort.
Similarly, there are conflicting reports on the association of
SPARC (secreted protein, acidic and rich in cysteine)
polymorphisms with SSc [12,13]. This lack of confirmation
may be due to the fact that Zhou and coworkers [12] studied
the Choctaw Indians, a relatively inbred group with homo-
geneous disease expression, whereas Lagan and coworkers
[13] studied a more heterogeneous scleroderma cohort. This
association must be confirmed (or rejected) in a scleroderma
cohort with diffuse disease and antitopoisomerase antibodies
(ATA). Until then, this association must be considered
unverified.
PTPN22 R620W polymorphism
The  PTPN22 gene encodes the lymphoid-specific protein
tyrosine phosphatase nonreceptor type 22, which resides on
on the short arm of chromosome 1 (area 1p13). The
presence of the minor allele R620W results in the
substitution of tryptophan for arginine at the binding site of
the protein, which disrupts its ability to bind to protein kinase,
Table 1
Gene regions significantly associated with systemic sclerosis
in the Choctaw Indian population
Region on chromosome Marker P value
1p32-31 D1S255 0.0068
1p21.2a D1S206 <0.0001
1q42.3a D1S2800 0.0012
5q33.2a D5S410 <0.0001
6p22.3a D6S422 0.0368
6q23-27a D6S264 0.0176
7p12-11a D7S510 0.0017
7q35 D7S661 0.005
8q24.12 D8S514 0.0015
14q21 D14S63 0.0173
15q21.1a D15S978 0.0189
19p13.2 D19S221 0.0016
19q13.2a D19S220 0.0175
20q12 D20S107 0.0095
22q13.1 D22S423 0.0005
Xp11.4 DXS1068 0.0026
Xq21-23 DXS8055 0.0082
aRegions that are common to systemic lupus erythematosus and/or
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thereby preventing its normal metabolism [14]. This increases
PTPN22 protein activity and, as a result, the threshold
required for T-cell receptor signalling in the thymus. It is
speculated that the mutation might induce autoimmunity by
preventing the deletion of autoreactive T cells, resulting in
insufficient activity in regulatory T cells.
A positive association of the PTPN22 R620W polymorphism
has been identified for patients with SSc, and more specifically
for the subgroup of SSc patients who are ATA positive and
those who are anticentromere antibody (ACA) positive [15].
This study evaluated 1,120 SSc patients and 816 control
individuals. The odds ratio in the ATA-positive patients
compared with control individuals was 2.36 (95% confidence
interval 1.5 to 3.6), and the odds ratio in the ACA-positive
patients was 1.71 (95% confidence interval 1.1 to 2.6). Two
other studies, namely those by Balada [16] and Wipff [17] and
colleagues, failed to find an association with this polymorphism,
but the number of cases and controls in these studies was
quite small (the Balada study included only 54 cases and 55
controls, whereas the Wipff study included 121 cases and 103
controls). Therefore, the negative findings in these latter two
studies are probably due to their being underpowered to
detect an association with an odds ratio of this magnitude.
Positive associations have been found for a number of other
immune diseases, including rheumatoid arthritis and systemic
lupus erythematosus (Table 3). The PTPN22 R620W poly-
morphism is not uniformly associated with autoimmune
diseases, however. There are some autoimmune diseases for
which no association with this particular polymorphism has
been found (Table 3; for review, see the report by Gregersen
and Batliwalla [18]).
AIF1 polymorphism
This polymorphism is located in the class III region, close to
the tumour necrosis factor gene cluster. The encoded
protein, allograft inflammatory factor 1, is detected in
vasculopathic vessels, for example after balloon angioplasty.
It is inducible in vascular smooth muscle cell cultures by
proinflammatory cytokines and promotes activation and
proliferation of vascular smooth muscles cells [19,20]. The
gene is upregulated in skin biopsies and peripheral blood
cells of scleroderma patients as compared with those of
matched control individuals in gene expression studies
[21-23].
Available online http://arthritis-research.com/content/9/S2/S5
Table 2
Candidate gene polymorphisms associated with systemic sclerosis
Encoded protein (gene location) Patient (n) Control (n) Association
TNF promoter (6p21.3) 214 354 -1031 C allele and -863 A allele strongly associated with ACA-positive SSc [37]
TNF-α (6p21.3) 114 170 -238 and +489 A alleles are weakly associated with SSc [38]
TNF-RII (chromosome 9) 114 170 TNF-RII -196 polymorphism is not associated with SSc [38]
MCP-1 promoter (17q11.2) 18 139 -2518 G/G phenotype is associated with SSc [39]
IL-1A (2q14) 60 70 IL-1A gene polymorphism is associated with SSc [40]
IL-1A (2q14) 46 150 IL-1A -889T allele is associated with SSc [41]
eNOS (7q36) 73 112 eNOS is associated with SSc [9]
eNOS (7q36) 77 49 eNOS G894T is not associated with SSc [10]
eNOS (7q36) 164 184 eNOS G894T is not associated with SSc [11]
SPARC (5q31.3-32) 20 75 SPARC polymorphisms are associated with SSc [12]
SPARC (5q31.3-32) 121 200 SPARC polymorphisms are not associated with SSc [13]
ACA, anticentromere antibody; eNOS, endothelial nitric oxide synthase; IL, interleukin; MCP, monocyte chemoattractant protein; SPARC, secreted
protein, acidic and rich in cysteine; TNF, tumour necrosis factor; TNF-RII, TNF receptor II.
Table 3
PTPN22 R620W polymorphism and links with immune diseases
Association identified No association
Scleroderma: ATA positive  Multiple sclerosis
and ACA positive
RA and JRA Coeliac disease
SLE Primary sclerosis cholangitis 
Type I diabetes mellitus Crohn’s disease
Grave’s and Addison’s Psoriasis
Psoriatic arthritis Ankylosing spondylitis
Wegener’s granulomatosis Primary Sjögren’s syndrome
This area of research is reviewed by Gregersen and Batliwalla [18].
ACA, anticentromere antibody; ATA, antitopoisomerase antibody; JRA,
juvenile rheumatoid arthritis; RA, rheumatoid arthritis; SLE, systemic
lupus erythematosus.A nonsynonymous SNP (AIF-1 gene SNP rs2269475) that
results in a tryptophan to arginine amino acid substitution is
found at a higher frequency in patients with SSc than in
control individuals [24]. To date, it is not clear whether the
amino acid substitution affects the function of the protein,
and therefore the functional significance of this change is
unknown.
HLA gene region polymorphisms
The HLA gene region is an extreme example of genetic
polymorphism. We recently completed a study of 1,100
patients in which we looked at several HLA class II
associations and were able to verify the findings of multiple
previous studies. Grouped by race or ethnicity, none of the
HLA associations were consistent in all groups. However,
grouped according to autoantibody status [25], for example
ATA, ACA, or RNA polymerase, the findings were consistent
between different ethnic groups. It therefore seems likely that
the gene associations may in fact be associated with sub-
phenotypes, particularly as defined by autoantibody
expression, rather than with SSc as a single disease entity.
An important area of future research will be to determine
whether these sub-phenotypes also predict response to
therapy.
Gene profiling in systemic sclerosis
In general, the molecular and cellular mechanisms that
maintain proper collagen homeostasis in healthy human skin
and are responsible for the dysregulated collagen synthesis
in SSc remain unknown. In an attempt to identify the genes
that are involved in this process, gene profiling studies have
been undertaken; gene profiling is a useful technique for
comparing gene expression between normal and diseased
cells. Gene profiling of SSc skin biopsies revealed robust
signatures of disease, identifying changes in expression of
about 1,800 genes that distinguish normal skin from SSc skin
at a significant level [22]. Alterations in transforming growth
factor-β and Wnt pathways, extracellular matrix proteins and
the CCN family were prominent. However, the changes
identified are not fully reflected in the profiles of explanted
fibroblasts. This observation suggests that studies conducted
in biopsy material are likely to prove more useful in the
complex disease pattern of SSc than cultured fibroblasts.
In addition to gene polymorphisms, epigenetic mechanisms
such as the degree of methylation or copy number variations
can change gene expression and result in a pathological
state. Such may be the case with Fli1.
The role of Fli1 in the pathogenesis of
systemic sclerosis
Fli1 expression in fibroblasts
Fli1 belongs to the family of Ets transcription factors that
were recently shown to be dysregulated in many immune
diseases [26]. Until relatively recently, Fli1 was considered to
be merely an immune cell transcription factor and was not
known to be expressed in fibroblasts. However, the finding
that Fli1 expression levels in cultured human and mouse
fibroblasts are inversely correlated with collagen type I
expression levels suggested that it may be a repressor of
collagen genes. Evidence for a role for Fli1 in regulating
collagen synthesis in cultured dermal fibroblasts and in
human skin in vivo was recently provided. Immunostaining for
Fli1 in normal skin biopsies revealed that although 70% of
fibroblasts were positive for Fli1, there was little evidence of
Fli1-positive fibroblasts in SSc skin biopsies (Figure 1). The
absence of Fli1 correlated with enhanced collagen synthesis
in SSc skin. Fli1 was shown to be required to maintain the
repressed state of the fibrillar collagen genes [27,28]. A
recent study suggested that epigenetic mechanisms may be
responsible for downregulation of Fli1 in SSc skin in vivo
[29].
In order to investigate how Fli1 maintains this repressed
state, the effects of Fli1 expression on regulation of genes
that were differentially expressed in SSc biopsies but not in
normal skin were examined [30]. This study showed that Fli1
directly regulates the expression of connective tissue growth
factor (CTGF), also known as CCN2. Downregulation of Fli1
upregulated expression of CTGF mRNA, which mimics to
some extent the profibrogenic effects of transforming growth
factor (TGF)-β. This is an important finding, because there is
little detectable TGF-β during fibrosis in SSc, other than
during the very early stage.
In addition to upregulation of CTGF, blocking Fli1 also
affected the expression of some other genes in the biopsy.
The expression of collagen mRNA was increased, as well as
that of PLOD2, which is known to be very important for
Arthritis Research & Therapy    Vol 9 Suppl 2 Mayes and Trojanowska
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Figure 1
Fli1 is absent in the majority of fibroblasts in SSc skin. Fli1, friend
leukaemia integration 1; NS, normal skin; SSc, systemic sclerosis.
Reprinted from Kubo et al. Am J Pathol 2003, 163:571-581 with
permission from the American Society for Investigative Pathology [27].collagen cross-linking [31]. As well as upregulating certain
genes in SSc biopsies, blocking Fli1 resulted in the
downregulation of others; one of these was the gene
encoding decorin, which also probably contributes to fibrillar
genesis.
Although the results from the in vitro studies on human
fibroblasts strongly suggested that reduced expression of
Fli1 had a profibrotic effect, this must also be demonstrated
in vivo. The Fli1-/- genotype is lethal, with mice dying from
cranial or spinal haemorrhages at day 11.5 [32]. Therefore, a
heterozygous model was initially used, with a 50% reduction
in Fli1 levels, which is viable and exhibits absolutely no
phenotype. Levels of interstitial collagen mRNA were only
slightly elevated in Fli1+/- mice; however, it could be
demonstrated that they produced elevated levels of acetic
acid extractable collagen and of type I collagen. Importantly,
an increase in fibril diameter by electron microscopy could
also be demonstrated, which is also found in SSc patients.
Homozygous Fli1 mice carrying a Fli1 gene that lacks a
carboxyl-terminal domain (Fli1∆CTA) were recently generated.
Fibroblasts from these mice maintain the activated phenotype
when cultured; these should prove useful in further
elucidating the role played by Fli1 in pathogenesis.
In summary, the recent observations provide valuable support
for the role of dysregulation of Fli1 in contributing to the
development of fibrosis in SSc. What is not yet clear is what
factors (genetic, environmental, or immunological) are
responsible for downregulating Fli1 in SSc.
Fli1 expression in the vascular compartment and its
potential role in vessel degradation
As well as being expressed in healthy fibroblasts, Fli1 is
highly expressed in endothelial cells, and probably in peri-
cytes and other cells around blood vessels. As well as being
downregulated in affected SSc skin, Fli1 is also down-
regulated in areas of uninvolved skin from SSc patients
(Figure 2).
Staining of microvessels in the homozygous Fli1∆CTA mice
compared with Fli1+/+ mice revealed downregulation of a
number of proteins that are known to be involved in
endothelial-mural interactions. These included smooth muscle
actin, desmin and platelet-derived growth factor receptor β.
Similar features were observed in human biopsies. In healthy
skin smooth muscle actin positive cells around the vessels
may be clearly observed near the epidermis and in deep
dermis. In SSc uninvolved skin we see malformed vessels
that are still partially covered by pericytes, and in SSc
involved skin we see very few vessels near the epidermis and
none in deep dermis (Figure 3).
A possible explanation for why vessels degenerate in SSc
relates to angiogenesis, because angiogenesis involves a
number of sequential steps, including the following: detach-
ment of pre-existing pericytes or vascular destabilization;
extracellular matrix degradation by endothelial proteases;
migration and proliferation of endothelial cells; tube formation
by endothelial cells; and, finally, reattachment of pericytes for
vascular stabilization [33,34]. In SSc skin it appears that the
vessels undergo proliferation when angiogenesis begins, but
they experience problems with reattachment of pericytes,
vessel maturation and stabilization. Using a three-dimensional
co-culture model to study the effect of Fli1 on dermal
microvascular endothelial cells covered by human collagen
and fibroblasts, we found that reducing Fli1 levels had a
proangiogenic effect, with increased tube formation, cell
migration and apoptosis in the collagen matrix [35]. These
Available online http://arthritis-research.com/content/9/S2/S5
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Figure 2
Fli1 is downregulated in microvessels in SSc skin. SSc, systemic
sclerosis. Reprinted from Kubo et al. Am J Pathol 2003, 163:571-581
with permission from the American Society for Investigative Pathology
[27].
Figure 3
Comparison of α-SMA staining in healthy and SSc skin. SMA, smooth
muscle actin; SSc, systemic sclerosis.findings suggest that in SSc there may be a problem with
vessel stability or maturation, or some kind of interaction
between endothelial cells and pericytes. Work in cancer has
shown that if pericytes are not present, then such vessels do
not survive [36].
Conclusion
Understanding of the genetic factors involved in SSc has
increased considerably in recent years. There is doubtless a
role for genes, in terms of either susceptibility or influencing
the phenotypic expression of the disease. On a broad level,
genetic studies are proving valuable in identifying genomic
regions with possible associations with SSc and, at the same
time, emphasizing the complexity of this disease, which
appears to represent a collection of phenotypes rather than a
single disease entity.
It is likely, based on results from PTPN22 studies and from
HLA studies, that there will be ‘general’ autoimmune disease
genes (such as PTPN22) and scleroderma specific genes
(like the HLA region associations). This area is undergoing
rapid change and is expected to provide new insights into
pathogenesis as well as therapeutic approaches.
The findings of gene profiling investigations are beginning to
provide us with possible mechanisms to explain, at least in
part, some of the complex pathogenesis that is involved in
SSc, with downregulation of Fli1 expression appearing to
play a central role. However, there remains much to learn,
including identification of the trigger(s) that result in the
development of this complex disease.
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